Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | GAA | P10253 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 4/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4846563 | 0.98 | KMT2A (0.73) | KMT2AMEN1GAATSHRHTT | |
| SCHEMBL27722453 | 0.89 | KMT2A (0.76) | KMT2AMEN1GAATSHRHTT | |
| SCHEMBL3862966 | 0.88 | KMT2A (0.59) | KMT2AMEN1GAATSHRHTT | |
| SCHEMBL1574735 | 0.88 | KMT2A (0.73) | KMT2AMEN1GAATSHRHTT | |
| SCHEMBL6069148 | 0.86 | SMN1; SMN2 (0.62) | KMT2AMEN1GAATSHRHTT | |
| SCHEMBL7608812 | 0.86 | KMT2A (0.71) | KMT2AMEN1GAATSHRHTT | |
| SCHEMBL892042 | 0.86 | KMT2A (0.71) | KMT2AMEN1GAATSHRHTT | |
| SCHEMBL7769050 | 0.86 | KMT2A (0.58) | KMT2AMEN1GAATSHRHTT | |
| SCHEMBL903110 | 0.86 | KMT2A (1.00) | KMT2AMEN1GAATSHRHTT | |
| SCHEMBL10929681 | 0.86 | KMT2A (0.71) | KMT2AMEN1GAATSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 393 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119790158-A | Methods and compositions relating to the synthesis of QS-7 molecules | 植物生物科学有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-119546753-A | Saponin biosynthetic enzymes | 植物生物科学有限公司 | 2025-02-28 | — | — | CN | claimed |
| CN-117062914-A | Methods and compositions | 植物生物科学有限公司 | 2023-11-14 | — | — | CN | claimed |
| CN-110642801-A | Preparation method of parecoxib meta-isomer impurity | 深圳市祥根生物科技有限公司 | 2020-01-03 | — | — | CN | claimed |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | claimed |
| US-20150080408-A1 | PYRIDINYL AMIDES AS P2X3 AND P2X2/3 INHIBITORS | ROCHE PALO ALTO LLC (US) | 2015-03-19 | — | — | US | claimed |
| US-8809326-B2 | Isoquinolinone Rho kinase inhibitors | AERIE PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | claimed |
| EP-2445868-B1 | BIPHENYL AMIDES USEFUL AS P2X3 AND/OR P2X2/3 RECEPTORS MODULATORS | HOFFMANN LA ROCHE (CH) | 2013-12-18 | — | — | EP | claimed |
| US-20130165443-A1 | BIPHENYL AND PHENYL-PYRIDINE AMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | BROKA CHRIS ALLEN (US) | 2013-06-27 | — | — | US | claimed |
| EP-1745009-B1 | HETEROARYL SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2012-11-14 | — | — | EP | claimed |
| WO-1998033786-A1 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-08-06 | — | — | WO | claimed |
| WO-1998034115-A1 | 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | claimed |
| WO-1998034111-A1 | TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | claimed |
| WO-1998002741-A9 | QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES | — | 1998-05-22 | — | — | WO | claimed |
| WO-1998002741-A1 | QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-01-22 | — | — | WO | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-0673784-A2 | Recording sheets containing oxazole, isooxazole, oxazolidinone, oxazoline salts, morpholine, thiazole, thiazolidine, thiadiazole, and phenothiazine compounds | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | EXOSC9, EXOSC5, EXOSC4 | KMT2A 2981/4885MEN1 2441/4885GAA 562/4885 |
| US-20150080408-A1 | PYRIDINYL AMIDES AS P2X3 AND P2X2/3 INHIBITORS | P2RX3, P2RX2, P2RX1 | KMT2A 3676/4885MEN1 2785/4885GAA 3642/4885 |
| US-20130165443-A1 | BIPHENYL AND PHENYL-PYRIDINE AMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | KMT2A 2959/4885MEN1 3518/4885GAA 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.